drugset / Trial / NCT01860729

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

NCT01860729

Phase 3 Completed 589 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the effects of anacetrapib on low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in participants with hypercholesterolemia when added to an existing statin therapy.

Timeline

Start
2013-05-13
Primary completion
2015-05-29
Completion
2015-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Anacetrapib Small molecule 100 mg Oral

Indications